Arcellx, Inc. (ACLX) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: 14.33
30Y Low14.3·High14.3
P/B Ratio
↑
16.10
↑+112% vs avg
5yr avg: 7.58
30Y Low5.5·High9.1
ROE
↑
-53.4%
↓+61% vs avg
5yr avg: -137.2%
30Y Low-452%·High-20%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ACLX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Arcellx, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.7B | $3.7B | $4.1B | $2.7B | $1.4B | — | — | — | — |
| Enterprise Value | $6.7B | $3.7B | $4.1B | $2.4B | $1.4B | — | — | — | — |
| P/E Ratio → | -28.27 | — | — | — | — | — | — | — | — |
| P/S Ratio | 302.09 | 164.73 | 38.06 | 24.18 | — | — | — | — | — |
| P/B Ratio | 16.10 | 9.12 | 9.03 | 5.50 | 6.67 | — | — | — | — |
| P/FCF | — | — | — | 14.33 | — | — | — | — | — |
| P/OCF | — | — | — | 12.85 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ACLX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 165.45 | 37.58 | 21.49 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | 12.73 | — | — | — | — | — |
ACLX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Arcellx, Inc. earns an operating margin of -1135.6%. Operating margins have compressed from -81.5% to -1135.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -53.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.0% | 70.0% | 95.2% | 100.0% | — | — | — | — | — |
| Operating Margin | -1135.6% | -1135.6% | -127.5% | -81.5% | — | — | — | — | — |
| Net Profit Margin | -1027.3% | -1027.3% | -99.5% | -64.1% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -53.4% | -53.4% | -22.8% | -20.5% | -452.3% | — | -360.6% | — | -59.5% |
| ROA | -34.8% | -34.8% | -14.0% | -12.4% | -85.3% | -69.7% | -63.4% | -60.5% | -52.5% |
| ROIC | -46.2% | -46.2% | -34.9% | -32.3% | -374.7% | — | — | — | — |
| ROCE | -46.6% | -46.6% | -21.3% | -18.6% | -103.1% | -78.2% | -69.0% | -65.9% | -59.4% |
ACLX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $16M ($96M total debt minus $80M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.24 | 0.24 | 0.12 | 0.20 | 0.43 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.04 | -0.11 | -0.61 | 0.12 | — | -0.92 | — | -1.04 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | -1.60 | — | — | — | — | — |
| Interest Coverage | -8.45 | -8.45 | -101.21 | -17.23 | -108.70 | -6495.90 | — | — | — |
ACLX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Arcellx, Inc.'s current ratio of 4.44x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 6.06x to 4.44x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.44 | 4.44 | 4.78 | 6.06 | 4.71 | 7.60 | 9.36 | 12.53 | 8.06 |
| Quick Ratio | 4.44 | 4.44 | 4.78 | 6.06 | 4.71 | 7.60 | 9.36 | 12.53 | 8.06 |
| Cash Ratio | 4.32 | 4.32 | 4.68 | 5.94 | 4.49 | 7.05 | 8.84 | 11.38 | 8.00 |
| Asset Turnover | — | 0.04 | 0.15 | 0.13 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 58.96 | — | — | — | — | — | — | — |
ACLX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Arcellx, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | 7.0% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $56M | $54M | $48M | $44M | $34M | $22M | $35M | $165581 |
Peer Comparison
Compare ACLX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ACLXYou | $7B | -28.3 | — | — | 70.0% | -1135.6% | -53.4% | -46.2% | — |
 LEGN | $5B | -9.0 | — | — | 60.3% | -13.3% | -29.1% | -12.7% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 CRSP | $5B | -8.5 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
 FATE | $264M | -2.0 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 ALLO | $530M | -2.7 | — | — | — | — | -53.4% | -41.7% | — |
 AUTL | $434M | -2.0 | — | — | -1293.5% | -2385.6% | -81.9% | -204.1% | — |
 BEAM | $3B | -39.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
 EDIT | $311M | -1.8 | — | — | — | — | -198.1% | — | — |
 IONS | $13B | -32.3 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See ACLX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ACLX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ACLX vs LEGN
Side-by-side business, growth, and profitability comparison vs Legend Biotech Corporation.
Start ComparisonACLX — Frequently Asked Questions
Quick answers to the most common questions about buying ACLX stock.
What is Arcellx, Inc.'s P/E ratio?
Arcellx, Inc.'s current P/E ratio is -28.3x. This places it at the 50th percentile of its historical range.
What is Arcellx, Inc.'s ROE?
Arcellx, Inc.'s return on equity (ROE) is -53.4%. The historical average is -161.5%.
Is ACLX stock overvalued?
Based on historical data, Arcellx, Inc. is trading at a P/E of -28.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Arcellx, Inc.'s profit margins?
Arcellx, Inc. has 70.0% gross margin and -1135.6% operating margin.